Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Abstract #CT11

Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers

Presenter: Bhavana Pothuri, Department of Obstetrics and Gynecology, New York University

Co-Authors: Lucy Gilbert, MD, McGill University Health Centre-RI; Anna V. Tinker, MD, BC Cancer; Renaud Sabatier, MD, Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille University; Valentina Boni, MD, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro; David M. O’Malley, MD, The Ohio State University–James CCC; Sharad Ghamande, MD, Georgia Cancer Center, Augusta University; Linda Duska, MD, Emily Couric Clinical Cancer Center, University of Virginia; Prafull Ghatage, MD, Department of Gynecological Oncology, University of Calgary; Wei Guo, GlaxoSmithKline; Ellie Im, GlaxoSmithKline; Ana Oaknin, MD, PhD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology

Background: Dostarlimab (TSR-042) is a humanized programmed death (PD)-1 receptor monoclonal antibody that blocks interaction with the PD-1 ligands. GARNET (NCT02715284) is a phase 1 study assessing antitumor activity and safety of dostarlimab monotherapy in patients with solid tumors.1

Objective: To explore the impact of mismatch repair status at the response to dostarlimab therapy in patients with recurrent or advanced endometrial cancer that progressed during or after a platinum-based chemotherapy regimen.

Methods: This multicenter, open-label, single-arm study included dose-escalation and expansion parts. We report on 2 independent expansion cohorts of patients with recurrent or advanced endometrial cancer associated with (1) mismatch repair-deficient (dMMR) or (2) mismatch repair-proficient (pMMR), as determined by immunohistochemistry (IHC), that progressed during or after a platinum-based chemotherapy regimen. Patients received 500 mg dostarlimab intravenously every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression, discontinuation, or withdrawal. The primary end points were the objective response rate (ORR) and duration of response (DOR), by blinded independent central review using RECIST v1.1.

Results: In total, 126 patients with dMMR and 145 with pMMR endometrial cancer identified by IHC were enrolled in the study and received dostarlimab. Of these, 103 and 142 patients, respectively, had sufficient follow-up time (24 weeks) for efficacy analyses. The mean follow-up was 16.3 months for patients with dMMR disease and 11.5 months for patients with pMMR disease. The ORR was 44.7% for patients with dMMR and 13.4% for patients with pMMR disease, with complete response seen in 10.7% and 2.1% of patients, respectively. Partial response was recorded in 34.0% of patients with dMMR disease and 11.3% of patients with pMMR disease; stable disease was recorded in 12.6% and 21.8% of patients, respectively. The disease control rate was 57.3% and 35.2%, respectively. Ongoing response was identified in 89.1% of patients with dMMR disease and 63.2% of patients with pMMR. The median DOR and overall survival were not reached. The 18-month DOR was 79.2% and 61.3%, respectively. The most common grade ≥3 treatment-emergent adverse events (AEs; N = 271) were anemia (12.2%), abdominal pain (4.8%), and dyspnea (4.1%). The most common grade ≥3 immune-related AEs were diarrhea, aspartate aminotransferase increased, and alanine aminotransferase increased (1.8% each). No treatment-related deaths occurred.

Conclusion: Dostarlimab demonstrated durable antitumor activity in patients with advanced or recurrent dMMR or pMMR endometrial cancer. dMMR status by IHC was associated with a higher response rate. No new safety signals were detected. These cohorts represent the largest prospective evaluation of a PD-1 (or PD-L1) therapy in endometrial cancer to date.

  1. Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6:1-7.
Related Items
Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy
August 2022 Clinical Trials to Clinical Practice published on August 23, 2022 in Clinical Trials, Melanoma
Evaluation of Clinical Pharmacy Services for Phase 1 Clinical Trials
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Original Article, Clinical Trials, Oncology Pharmacy Protocols
Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Gynecologic Cancers, Biomarkers, Checkpoint Inhibitors
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Impact of PGY2 Oncology Pharmacy Residents’ Learning Experiences During the COVID-19 Pandemic
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.